These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2029694)

  • 1. Cognitive processes in idiopathic dystonia treated with high-dose anticholinergic therapy: implications for treatment strategies.
    Taylor AE; Lang AE; Saint-Cyr JA; Riley DE; Ranawaya R
    Clin Neuropharmacol; 1991 Feb; 14(1):62-77. PubMed ID: 2029694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose anticholinergic therapy in adult dystonia.
    Lang AE
    Can J Neurol Sci; 1986 Feb; 13(1):42-6. PubMed ID: 2869832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of acute antimuscarinic drugs for the chronic efficacy of antimuscarinic drugs in adults with focal dystonia.
    Tanner CM; Wilson RS; Goetz CG; Shannon KM
    Adv Neurol; 1988; 50():557-60. PubMed ID: 3400510
    [No Abstract]   [Full Text] [Related]  

  • 4. High-dosage anticholinergic therapy in dystonia.
    Fahn S
    Adv Neurol; 1983; 37():177-88. PubMed ID: 6134442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained-release anticholinergics in dystonia: case report.
    Samie MR
    Neurology; 1987 May; 37(5):885-6. PubMed ID: 3574699
    [No Abstract]   [Full Text] [Related]  

  • 6. High dosage anticholinergic therapy in dystonia.
    Fahn S
    Neurology; 1983 Oct; 33(10):1255-61. PubMed ID: 6136938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapy of dystonia.
    Fahn S
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):528-32. PubMed ID: 3315156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety and tolerance of single-dose botulinum toxin Type A treatment in 204 patients with spasticity and localized associated symptoms. Austrian and German botulinum toxin A spasticity study group].
    Wissel J; Müller J; Heinen F; Mall V; Sojer M; Ebersbach G; Poewe W
    Wien Klin Wochenschr; 1999 Oct; 111(20):837-42. PubMed ID: 10586488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cranial dystonia: double-blind crossover study of anticholinergics.
    Nutt JG; Hammerstad JP; deGarmo P; Carter J
    Neurology; 1984 Feb; 34(2):215-7. PubMed ID: 6363970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paroxysmal dystonia responsive to anticholinergic drugs.
    Micheli F; Fernandez Pardal M; de Arbelaiz R; Lehkuniec E; Giannaula R
    Clin Neuropharmacol; 1987 Aug; 10(4):365-9. PubMed ID: 3503680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dystonia: therapy with high dosage anticholinergic medication.
    Reddy RV; Siemers ER
    Indiana Med; 1987 Jun; 80(6):552-3. PubMed ID: 2886522
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.
    Litvan I; Blesa R; Clark K; Nichelli P; Atack JR; Mouradian MM; Grafman J; Chase TN
    Ann Neurol; 1994 Jul; 36(1):55-61. PubMed ID: 8024262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients.
    Cooper JA; Sagar HJ; Doherty SM; Jordan N; Tidswell P; Sullivan EV
    Brain; 1992 Dec; 115 ( Pt 6)():1701-25. PubMed ID: 1486457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances in the treatment of the dystonias].
    Giménez-Roldán S
    Arch Neurobiol (Madr); 1991; 54(5):198-205. PubMed ID: 1804033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advances in the treatment of the dystonias].
    Giménez-Roldán S
    Arch Neurobiol (Madr); 1991; 54 Suppl 3():32-9. PubMed ID: 1810206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial.
    Brans JW; Lindeboom R; Snoek JW; Zwarts MJ; van Weerden TW; Brunt ER; van Hilten JJ; van der Kamp W; Prins MH; Speelman JD
    Neurology; 1996 Apr; 46(4):1066-72. PubMed ID: 8780093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ACTH and the effects of anticholinergic drugs in dystonia.
    Sandyk R
    Int J Neurosci; 1989 Mar; 45(1-2):123-6. PubMed ID: 2541093
    [No Abstract]   [Full Text] [Related]  

  • 18. Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed.
    Flicker C; Serby M; Ferris SH
    Psychopharmacology (Berl); 1990; 100(2):243-50. PubMed ID: 2305013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained attention in cranial dystonia patients treated with botulinum toxin.
    Allam N; Frank JE; Pereira C; Tomaz C
    Acta Neurol Scand; 2007 Sep; 116(3):196-200. PubMed ID: 17714334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls.
    Broocks A; Little JT; Martin A; Minichiello MD; Dubbert B; Mack C; Tune L; Murphy DL; Sunderland T
    Biol Psychiatry; 1998 Mar; 43(6):408-16. PubMed ID: 9532345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.